Download citation
BibTeX (.bib)
Bookends (.ris)
EasyBib (.ris)
EndNote (.enw)
EndNote 8 (.xml)
ISI WoS (.isi)
Medlars (.medlars)
Mendeley (.ris)
MODS (.xml)
Papers (.ris)
RefWorks (.txt)
RefManager (.ris)
RIS (.ris)
MS Word (.xml)
Zotero (.ris)
References
- Reaven GM. Non-insulin-dependent diabetes mellitus, abnormal lipoprotein metabolism, and atherosclerosis. Metabolism 1987; 36 (Suppl 1):1-8.
Go to original source...
Go to PubMed...
- Šochman J. Nemoc tučných jater a statiny - kterému oboru patří tento problém? Čas Lék čes 2006;145:443-6.
- Hradec J. Endokanabinoidní systém - nový léčebný cíl u multirizikových nemocných. Remedia 2005;15:163-8.
- Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. RIO-North America Study Group. Effect of rimonabant, a cannabionoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-75.
Go to original source...
Go to PubMed...
- Despres JP, Golay A, Sjostrom L. Rimonabant in Obesity-Lipids Study group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New Engl J Med 2005;353:2121-34.
Go to original source...
Go to PubMed...